{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:31:11Z","timestamp":1793223071685,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T00:00:00Z","timestamp":1659225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.contraception.2022.07.010","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T01:45:22Z","timestamp":1659318322000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Pooled analysis of two phase 3 trials evaluating the effects of a novel combined oral contraceptive containing estetrol\/drospirenone on bleeding patterns in healthy women"],"prefix":"10.1016","volume":"116","author":[{"given":"Andrew M.","family":"Kaunitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Achilles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Zatik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Weyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terhi","family":"Piltonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Suturina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inna","family":"Apolikhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Bouchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn L.","family":"Westhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Jost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Michel","family":"Foidart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell D.","family":"Creinin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2022.07.010_bib0001","unstructured":"United Nations Department of Economic and Social Affairs. Contraceptive Use by Method 2019. https:\/\/www.un.org\/development\/desa\/pd\/sites\/www.un.org.development.desa.pd\/files\/files\/documents\/2020\/Jan\/un_2019_contraceptiveusebymethod_databooklet.pdf (accessed 30 June 2022)."},{"key":"10.1016\/j.contraception.2022.07.010_bib0002","first-page":"299","article-title":"Pharmacological profile of estrogens in oral contraception","volume":"63","author":"Bitzer","year":"2011","journal-title":"Minerva Ginecol"},{"key":"10.1016\/j.contraception.2022.07.010_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010813.pub2","article-title":"Combined oral contraceptives: venous thrombosis","author":"de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2022.07.010_bib0004","doi-asserted-by":"crossref","first-page":"f5298","DOI":"10.1136\/bmj.f5298","article-title":"Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis","volume":"347","author":"Stegeman","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2022.07.010_bib0005","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/09513590.2012.662547","article-title":"An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate\/dienogest","volume":"28","author":"Fruzzetti","year":"2012","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.contraception.2022.07.010_bib0006","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/AOG.0b013e3182a1741c","article-title":"Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive","volume":"122","author":"Archer","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2022.07.010_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003989.pub5","article-title":"20 microg versus >20 microg estrogen combined oral contraceptives for contraception","author":"Gallo","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.contraception.2022.07.010_bib0008","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.contraception.2016.12.001","article-title":"Pooled analysis of two randomized, open-label studies comparing the effects of nomegestrol acetate\/17beta-estradiol and drospirenone\/ethinyl estradiol on bleeding patterns in healthy women","volume":"95","author":"Mansour","year":"2017","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.07.010_bib0009","doi-asserted-by":"crossref","first-page":"264","DOI":"10.3109\/13625187.2013.780202","article-title":"Efficacy and bleeding profile of a combined oral contraceptive containing oestradiol valerate\/dienogest: a pooled analysis of three studies conducted in North America and Europe","volume":"18","author":"Nelson","year":"2013","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2022.07.010_bib0010","doi-asserted-by":"crossref","first-page":"d6423","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9","volume":"343","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2022.07.010_bib0011","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231856","article-title":"Bleeding profile of women using a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg","volume":"15","author":"Palacios","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.contraception.2022.07.010_bib0012","doi-asserted-by":"crossref","first-page":"34628","DOI":"10.18632\/oncotarget.26015","article-title":"The clinical relevance of progestogens in hormonal contraception: present status and future developments","volume":"9","author":"Regidor","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.contraception.2022.07.010_bib0013","first-page":"207","article-title":"Metabolism of 17-beta-oestradiol-4-14-C in early infancy","volume":"49","author":"Hagen","year":"1965","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.contraception.2022.07.010_bib0014","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.contraception.2016.04.015","article-title":"Bleeding pattern and cycle control with estetrol-containing combined oral contraceptives: results from a phase II, randomised, dose-finding study (FIESTA)","volume":"94","author":"Apter","year":"2016","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.07.010_bib0015","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.contraception.2021.05.002","article-title":"Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results","volume":"104","author":"Creinin","year":"2021","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.07.010_bib0016","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/1471-0528.16840","article-title":"Estetrol-Drospirenone combination oral contraceptive: a clinical study of contraceptive efficacy, bleeding pattern and safety in Europe and Russia","volume":"129","author":"Gemzell-Danielsson","year":"2022","journal-title":"BJOG"},{"key":"10.1016\/j.contraception.2022.07.010_bib0017","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.contraception.2007.06.008","article-title":"Contraceptive discontinuation attributed to method dissatisfaction in the United States","volume":"76","author":"Moreau","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.07.010_bib0018","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2307\/2991665","article-title":"Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation","volume":"30","author":"Rosenberg","year":"1998","journal-title":"Fam Plann Perspect"},{"key":"10.1016\/j.contraception.2022.07.010_bib0019","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajog.2018.12.022","article-title":"Predictors of contraceptive switching and discontinuation within the first 6 months of use among Highly Effective Reversible Contraceptive Initiative Salt Lake study participants","volume":"220","author":"Simmons","year":"2019","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2022.07.010_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.contraception.2006.08.012","article-title":"Recommendations for standardization of data collection and analysis of bleeding in combined hormone contraceptive trials","volume":"75","author":"Mishell","year":"2007","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2022.07.010_bib0021","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/aje\/kwr356","article-title":"Menstrual bleeding patterns among regularly menstruating women","volume":"175","author":"Dasharathy","year":"2012","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.contraception.2022.07.010_bib0022","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejogrb.2012.01.021","article-title":"A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 mug\/drospirenone 3 mg administered in a 21\/7 regimen versus ethinylestradiol 20 mug\/drospirenone 3 mg administered in a 24\/4 regimen","volume":"162","author":"Marr","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.contraception.2022.07.010_bib0023","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.contraception.2015.09.013","article-title":"Body mass index does not affect the efficacy or bleeding profile during use of an ultra-low-dose combined oral contraceptive","volume":"93","author":"Nakajima","year":"2016","journal-title":"Contraception"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782422002189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782422002189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:22:15Z","timestamp":1757881335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782422002189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":23,"alternative-id":["S0010782422002189"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2022.07.010","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pooled analysis of two phase 3 trials evaluating the effects of a novel combined oral contraceptive containing estetrol\/drospirenone on bleeding patterns in healthy women","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2022.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}